Squamous Cell Anal Carcinoma clinical trials

Explore recruiting squamous cell anal carcinoma clinical trials.

Recruiting squamous cell anal carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Squamous Cell Anal Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

INTERACT-ION : Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study.

France

Therapeutic exploratory (Phase II) EU CTIS Study details

SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Squamous Cell Anal Carcinoma trials by city

Squamous Cell Anal Carcinoma clinical trials

Recruiting squamous cell anal carcinoma studies right now

Phase III Study Evaluating Induction Chemotherapy Followed by Chemoradiotherapy Compared to Standard Chemoradiotherapy for Locally Advanced SCCA

Sintilimab Versus Mitomycin in Combination With Capecitabine and IMRT for Limited-stage Anal Squamous Cell Carcinoma

Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase

SMP-3124LP in Adults With Advanced Solid Tumors

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis

Screening Strategies Among High-risk Populations for Anal Cancer

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.

Also recruiting in Europe

INTERACT-ION : Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin and 5-fluorouracil) followed by chemoradiotherapy in patients with stage III squamous cell anal carcinoma. A phase II study.

SPARTANA : Spartalizumab, mDCF (docetaxel, cisplatin and 5-fluorouracil) and radiotherapy in patients with metastatic squamous cell anal carcinoma. A Phase IIA study

Squamous Cell Anal Carcinoma trials by city

Other conditions